Soleno Therapeutics (SLNO) Notes Payables (2015)

Soleno Therapeutics' (SLNO) quarterly Notes Payables came in at $865000.0 in Q4 2015, down 77.54% on a QoQ basis from $3.9 million in Q3 2015.

Soleno Therapeutics (SLNO) Notes Payables (2015) Analysis & Trends

Soleno Therapeutics (SLNO) has 1 years of Notes Payables data on file, last reported at $865000.0 in Q4 2015.

On a quarterly basis, Notes Payables changed N/A year-over-year to $865000.0 in Q4 2015; TTM through Dec 2015 was $865000.0, a N/A change from a year earlier, with the FY2015 full-year figure at $865000.0, changed N/A from the prior year.
Notes Payables for Q4 2015 stood at $865000.0, down from $3.9 million in the prior quarter.
Over the last five years, Notes Payables for SLNO reached as high as $11.0 million in Q2 2015 and fell as low as $865000.0 in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Soleno Therapeutics	874.25 Mn	618.67 Mn	93.41 Mn

Download Data